|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Whole-body heat exposure induces membrane changes in spermatozoa from the cauda epididymidis of laboratory mice显示文摘这研究被执行决定到热环境温度的暴露是否在精子质量上有直接、有害效果。为这,实验室老鼠的 epididymal 精子上的整个身体的热暴露的效果被调查。C57BL/6 鼠标(n = 7 ) 是在在 37 掳 C 鈥 ? 的一个小气候房间的 housed 为 8 h 的 8 掳 C 每为三连续的天的天,当时控制鼠标(n = 7 ) 在 23 掳 C 被保留鈥 ? 4 掳 C。尾 epididymal 精子被获得在最后热处理以后的 16 h。结果证明精子号码在二个组是类似的(P = 0.23 ) ,但是在热处理以后,在能动精子的百分比的重要减小是在场的(P < 0.0001 ) 。精子的膜变化被与结合的藻红朊(PE ) 染色 Annexin V 调查,它检测 phosphotidylserine 的 exteriorization 从对精子血浆膜,和 7-aminoactinomycin D (7-AAD ) 的外部传单内部,当血浆膜被损坏时,它绑在精子原子核。显示出与 Annexin V 鈥揚E 或 7-AAD 或两个的积极染色的精子的百分比,显著地更高(P < 0.05 ) 在暴露热的老鼠与控制相比。这些结果显示出那整个身体的热暴露到 8 掳 C 导致的 37 掳 C 鈥 ? 膜在老鼠的 epididymal 精子变化,它可以导致 apoptosis。 | Harsha Wechalekar Brian P. Setchell Eleanor J. Peirce Mario Ricci Chris Leigh William G. Breed | 2010 | Asian Journal of Andrology2010，12，4： | 4 |
| 2 | Utility of arthroscopic guided synovial biopsy in understanding synovial tissue pathology in health and disease states显示文摘The synovium is the soft tissue lining diarthrodial joints, tendon sheaths and bursae and is composed of intimal and subintimal layers. The intimal layer is composed of type A cells(macrophages) and type B cells(fibroblasts); in health, the subintima has few inflammatory cells. The synovium performs several homeostatic functions and is the primary target in several inflammatory arthritides. Inflammatory states are characterised by thickening of the synovial lining, macrophage recruitment and fibroblast proliferation, and an influx of inflammatory cells including lymphocytes, monocytes and plasma cells. Of the various methods employed to perform synovial biopsies arthroscopic techniques are considered the 'gold standard', and have an established safety record. Synovial biopsy has been of critical importance in understanding disease pathogenesis and has provided insight into mechanisms of action of targeted therapies by way of direct evidence about eventsin the synovial tissue in various arthritides. It has been very useful as a research tool for proof of concept studies to assess efficacy and mechanisms of new therapies, provide tissue for in vitro studies, proteomics and microarrays and allow evaluation for biomarkers that may help predict response to therapy and identify new targets for drug development. It also has diagnostic value in the evaluation of neoplastic or granulomatous disease or infection when synovial fluid analysis is noncontributory. | Mihir D Wechalekar Malcolm D Smith | 2014 | World Journal of Orthopedics2014，5，5： | 4 |
| 3 | Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease显示文摘 | Wechalekar AD Lachmann HJ | 2008 | Haematologica2008，93，2： | 1 |
| 4 | Colchicine for acute gout显示文摘 | Van Echteld I Wechalekar MD Schlesinger N | 2014 | Cochrane Database Syst Rev2014，8，00： | 1 |
| 5 | Guidelines onthe diagnosis and investigation of AL amyloidosis显示文摘 | GILLMORE JD WECHALEKAR A BIRD J | 2015 | Br J Haema-tol2015，168，2： | 1 |
| 6 | IgD multiplemyeloma-a clinical profile and outcome with chemotherapy and autologous stem cell transplantation显示文摘 | WECHALEKAR A AMATO D CHEN C | 2005 | Ann Hemato2005，84，2： | 1 |
| 7 | Intermediate dose thalidomide (200 mg daily) has comparable efficacy and less toxicity than higher doses in relapsed multiple myeloma显示文摘 | WECHALEKAR A D CHEN C I SUTTON D | 2003 | Leuk Lymphoma2003，44，： | 1 |
| 8 | Radionuclide imaging in ischaemic heart failure显示文摘 | Stirrup J Maenhout A Wechalekar K | 2009 | Br Med Bull2009，92，： | 1 |
| 9 | Intermediate does thalidomide (200 mg daily) has comparable efficacy and less toxicity than higher does in relapsed multiple myeloma显示文摘 | Wechalekar AD Chen CI Sutton D | 2003 | Leuk Lyre Phoma2003，44，7： | 1 |
| 10 | A European collaborative study of treatment outcomes in 346 patients with cardiac stage lII AL amyloidosis 显示文摘 | Wechalekar AD Schonland SO Kastritis E | 2013 | Blood2013，121，17： | 1 |
| 11 | Radionuclide imaging in ischaemic heart failure 显示文摘 | Stirrup J Maenhout A Wechalekar K | 2009 | Br Med Bull2009，92，： | 1 |
| 12 | Safety and efficacy of risk-adapted eyelophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis显示文摘 | Wechalekar AD Goodman HJ LaehmannIII | 2007 | Blood2007，109，2： | 1 |
| 13 | Safety and efficacy of risk-adapted cyclophosphamide,thalidomide,and dexamethasone insystemic AL amyloidosis显示文摘 | Wechalekar AD Goodman HJ Lachmann HJ | 2007 | Blood2007，109，： | 1 |
| 14 | Efficacy and safety of bortezomib in systemic AL amyloidosis-A preliminary report显示文摘 | Wechalekar A Gillmore J Lachmannl H | 2006 | Blood(ASH Annual Meeting Abstracts)2006，108，11： | 1 |
| 15 | Cardiac amyloidosis, a monoclonal gammopathy and a potentially misleading mutation显示文摘 | Wechalekar AD Offer M Gillmore JD | 2009 | Nat Clin Pract Cardiovasc Med2009，6，： | 1 |
| 16 | Bortezomib with or without dexamethasone in primary (light chain) systemic amyloidosis显示文摘 | Kastritis E Wechalekar AD Dimopoulos MA | 2010 | J ClinOncol2010，28，6： | 1 |
| 17 | Safety and efficacy of risk-adapted cyclophosphamide,thalidomide,and dexamethasone in systemic AL amyloidosis显示文摘 | Wechalekar AD Goodman HJB Lachmann HJ | 2007 | Blood2007，109，2： | 1 |
| 18 | IgD multiple myeloma a clinical profile and outcome with chemotherapy and autologous stem cell transplantation显示文摘 | Wechalekar A Amato D Chen C | 2005 | Ann Hematol2005，84，： | 1 |
| 19 | Imaging in systemic amyloidosis显示文摘 | Sachchithanantham S Wechalekar AD | 2013 | Br Med Bull2013，107，1： | 1 |
| 20 | Acute myo- cardial infarc-tion during adenosine myocardial perfusion imaging显示文摘 | Reyes E Wechalekar K Loong CY | 2004 | J Nucl Cardiol2004，11，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员